Fernández Calvo Ovidio, Muñoz Iglesias José, Abou Jokh Casas Estephany, Molina-Díaz Aura, Anido Herranz Urbano, Casas Nebra Javier, García-Bernardo Lucía, Martínez-Breijo Sara, Lázaro-Quintela Martín, Muñiz-García Gloria, Vázquez-Estevez Sergio
Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Department of Nuclear Medicine (SERGAS), University Hospital of Vigo, Meixoeiro Hospital, Vigo, Spain.
Clin Transl Oncol. 2025 Apr;27(4):1383-1397. doi: 10.1007/s12094-024-03662-7. Epub 2024 Sep 12.
Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [Ga] and [F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [Lu]Lu-PSMA-617 in patients with PC.
治疗诊断学是一种精准医学，它使用与放射性同位素相连的分子来诊断和治疗疾病。近年来，它在治疗神经内分泌肿瘤方面变得尤为重要，目前也用于前列腺癌的治疗。已经出现了各种放射性药物，用于在正电子发射断层扫描/计算机断层扫描上诊断和检测显示前列腺特异性膜抗原（PSMA）阳性的病变，其中使用最广泛的是标记有[镓]和[氟]的药物。其在前列腺癌（PC）治疗中的应用已在使用放射性配体[镥]Lu-PSMA-617进行的VISION、TheraP和PSMAfore临床试验中得到评估，显示出显著的抗肿瘤活性。本文的目的是基于当前可用的科学证据和多学科共识，为PC患者使用[镥]Lu-PSMA-617进行诊断和治疗提供实用建议。
